Summary
Vasculitis is a family of rare autoimmune diseases, causing inflammation of the blood vessels, arteries, veins or capillaries. The different forms of vasculitis are classified by the size and location of the affected blood vessels . This report specifically covers large vessel vasculitis (LLV), Kawasaki disease (KD), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and Behçet's disease (BD). In 2014, there were 137,603 and 82,454 diagnosed prevalent and incident cases in the 7MM (US, France, Germany, Spain, Italy, UK, and Japan), respectively. Untreated, the organs and tissues affected by the damaged blood vessels do not get enough blood, which can lead to organ or tissue damage, or even death. J&J's Remicade was the first biologic in the vasculitis market, approved for BD in Japan in 2007. Other biologics approved for vasculitis include AbbVie's Humira for BD in Japan and Biogen/Roche's Rituxan for GPA/MPA in the 7MM. Several unmet needs still remain such as the development of drugs with improved safety and efficacy for use in both the induction and maintenance treatment settings . GlobalData expects the launch of six drugs during the 2014 to 2024 forecast period along with increased diagnosed patient numbers will drive the vasculitis market.
Highlights
Key Questions Answered
- How large an impact will biosimilars have on the vasculitis market? What do vasculitis specialists and key opinion leaders across the 7MM think about the evolving treatment landscape?
- What opportunities remain in the market for new product entrants?
- With six drug launches, five of which are biologics, which products are forecast to generate the highest sales over 2014-2024? How are product launches expected to affect the sales of induction and maintenance therapies?
- According to KOLs, what are the most important unmet needs in vasculitis? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2024?
- What industry developments are likely to affect sales of the top-selling vasculitis drugs in the markets researched? Which is the largest growth market globally?
Key Findings
- Biosimilars are expected to change the landscape for vasculitis and create pricing pressure in the vasculitis market. However, questions from physicians and regulators regarding the appropriate use of biosimilars still lingers.
- Sales of immunosuppressants are expected to decline due to the introduction of novel biologics and small molecules to treat vasculitis.
- Several unmet needs are expected to remain after the forecast period, as all pipeline drugs are in development as induction therapies and maintenance therapies are lagging.
- With several major pharmaceutical companies involved in development of vasculitis products, the market will be dominated by Big Pharma who will leverage their R&D, manufacturing, and distribution networks.
Scope
- Overview of vasculitis, including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.
- Annualized vasculitis market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the vasculitis market.
- Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically BMS’s Orencia, GSK’s Benlysta and Nucala, Genentech/Roche’s Actemra, Celgene’s Otezla, J&J’s Remicade, and biosimilars (such as Celltrion/Hospira/Alvogen’s Inflectra/Remsima).
- Analysis of the current and future market competition in the global vasculitis market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the vasculitis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global vasculitis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global vasculitis market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
'
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Types of Vasculitis
3.2 Etiology and Pathophysiology
3.2.1 Large Vessel Vasculitis
3.2.2 Kawasaki Disease
3.2.3 ANCA-Associated Small Vessel Vasculitis
3.2.4 Beh?et’s Disease
3.3 Symptoms
3.4 Disease Management
3.4.1 Classification Criteria
3.4.2 Disease Management Guidelines
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Sources Not Used
4.4.3 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for Vasculitis, 2014-2024
4.5.1 Diagnosed Incident Cases of AAV
4.5.2 Diagnosed Prevalent Cases of AAV
4.5.3 Age-Standardized Incidence of AAV
4.5.4 Diagnosed Incident Cases of LVV - TA and GCA
4.5.5 Diagnosed Prevalent Cases of TA
4.5.6 Age-Standardized Incidence of LVV
4.5.7 Diagnosed Incident Cases of BD
4.5.8 Diagnosed Prevalent Cases of BD
4.5.9 Age-Standardized Incidence of BD
4.5.10 Diagnosed Incident Cases of KD
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Current Treatment Options
5.1 Overview
5.2 Product Profiles
5.2.1 Rituxan (Rituximab)
5.2.2 Humira (Adalimumab)
5.2.3 Remicade (Infliximab)
5.2.4 Mycophenolate Mofetil
5.2.5 Cyclophosphamide
5.2.6 Azathioprine
5.2.7 Methotrexate
5.2.8 Glucocorticoids
5.2.9 Intravenous Immunoglobulin
6 Unmet Needs Assessment and Opportunity Analysis
6.1 Overview
6.2 Improved Drug Efficacy and Safety in the Induction Therapy Setting
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Improved Drug Efficacy and Safety in the Maintenance Therapy Setting
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Biomarkers to Predict Responsiveness to Therapy
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Biomarkers to Predict Disease Relapse
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Early and Non-invasive Diagnosis of Vasculitis
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Adjunctive Therapy for the Treatment of KD
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
7 R&D Strategies
7.1 Overview
7.2 Expansion for Key Autoimmune Drugs
7.3 Shift Towards Vasculitis as a Primary Indication
7.4 Clinical Trial Design
7.4.1 Current Clinical Trial Design
7.4.2 Challenges in Vasculitis Clinical Trial Design
8 Pipeline Assessment
8.1 Overview
8.2 Promising Drugs in Clinical Development
8.2.1 Orencia (Abatacept)
8.2.2 Benlysta (Belimumab)
8.2.3 Actemra (Tocilizumab)
8.2.4 Otezla (Apremilast)
8.2.5 Nucala (Mepolizumab)
8.3 Additional Drugs in Development for Vasculitis
9 Pipeline Valuation Analysis
9.1 Clinical Benchmark of Key Pipeline Drugs
9.1.1 AAV
9.1.2 LVV
9.1.3 KD
9.1.4 BD
9.2 Commercial Benchmark of Key Pipeline Drugs
9.2.1 AAV
9.2.2 LVV
9.2.3 KD
9.2.4 BD
9.3 Competitive Assessment
9.3.1 AAV
9.3.2 LVV
9.3.3 KD
9.3.4 BD
9.4 Top Line Ten Year Forecast
9.4.1 US
9.4.2 5EU
9.4.3 Japan
10 Appendix
10.1 Bibliography
10.2 Abbreviations
10.3 Methodology
10.4 Forecasting Methodology
10.4.1 Percent Drug-treated Patients
10.4.2 Drugs Included in Each Therapeutic Class
10.4.3 Launch and Patent Expiry Dates
10.4.4 General Pricing Assumptions
10.4.5 Individual Drug Assumptions
10.4.6 Generic Erosion
10.4.7 Pricing of Pipeline Agents
10.5 Primary Research
10.5.1 Physicians and Specialists Included in this Study
10.5.2 Online Survey of High Prescribing Physicians
10.6 About the Authors
10.6.1 Author
10.6.2 Reviewer
10.6.3 Epidemiologist
10.6.4 Global Director of Therapy Analysis and Epidemiology
10.6.5 Global Head of Healthcare
10.7 About Us
10.8 Disclaimer
1.1 List of Tables
Table 1: Symptoms of Selected Types of Vasculitis
Table 2: Nine Recommendations for the Management of BD
Table 3: Clinical and Laboratory Features of KD
Table 4: Risk Factors and Comorbidities for Vasculitis
Table 5: 2012 Revised CHCC Definitions of Vasculitides
Table 6: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of MPA
Table 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of MPA
Table 8: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of GPA
Table 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of GPA
Table 10: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of eGPA
Table 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of eGPA
Table 12: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of GCA
Table 13: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of TA
Table 14: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of TA
Table 15: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of BD
Table 16: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of BD
Table 17: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of KD
Table 18: 7MM, Sources Not Used in Epidemiological Analysis of AAV, LVV, BD, and KD
Table 19: 7MM, Diagnosed Incident Cases of AAV, Ages =15 Years, Both Sexes, N, 2014-2024
Table 20: 7MM, Diagnosed Prevalent Cases of AAV, Ages =15 Years, Both Sexes, N, 2014-2024
Table 21: 7MM, Diagnosed Incident Cases of LVV, Ages =15 Years, Both Sexes, N, 2014-2024
Table 22: 7MM, Diagnosed Prevalent Cases of TA, Ages =15 Years, Both Sexes, N, 2014-2024
Table 23: 7MM, Diagnosed Incident Cases of BD, Ages =15 Years, Both Sexes, N, 2014-2024
Table 24: 7MM, Diagnosed Prevalent Cases of BD, Ages =15 Years, Both Sexes, N, 2014-2024
Table 25: 7MM, Diagnosed Incident Cases of KD, Ages =5 Years, Both Sexes, N, 2014-2024
Table 26: Leading Treatments for Vasculitis, 2015
Table 27: Current Treatment Options for Vasculitis Across the 7MM, November 2015
Table 28: Product Profile - Rituxan
Table 29: Rituxan SWOT Analysis, 2015
Table 30: Product Profile - Humira
Table 31: Humira SWOT Analysis, 2015
Table 32: Product Profile - Remicade
Table 33: Completed trials demonstrating Remicade as a potential treatment for vasculitis
Table 34: Remicade SWOT Analysis, 2015
Table 35: Product Profile - Mycophenolate Mofetil
Table 36: Evidence for Mycophenolate Mofetil Treatment Therapy in Vasculitis
Table 37: MMF SWOT Analysis, 2015
Table 38: Product Profile - CYC
Table 39: Evidence for cyclophosphamide treatment therapy in vasculitis
Table 40: CYC SWOT Analysis, 2014
Table 41: Product Profile - Azathioprine
Table 42: Evidence for azathioprine treatment therapy in vasculitis
Table 43: Azathioprine SWOT Analysis, 2015
Table 44: Product Profile - Methotrexate
Table 45: Evidence for Methotrexate treatment therapy in vasculitis
Table 46: Methotrexate SWOT Analysis, 2015
Table 47: Product Profile - Glucocorticoids
Table 48: Evidence for Glucocorticoid Treatment Therapy in Vasculitis
Table 49: GC SWOT Analysis, 2015
Table 50: Product Profile - Intravenous Immunoglobulin
Table 51: Evidence for Intravenous Immunoglobulin Therapy in Vasculitis
Table 52: GC SWOT Analysis, 2015
Table 53: Unmet Need and Opportunity in Vasculitis, 2015
Table 54: Vasculitis - Late Stage Pipeline, December 2015
Table 55: Product Profile - Orencia
Table 56: Orencia SWOT Analysis, 2015
Table 57: Product Profile - Benlysta
Table 58: Benlysta SWOT Analysis, 2015
Table 59: Product Profile - Actemra
Table 60: Clinical Trials Demonstrating Actemra as a Potential Treatment for Vasculitis
Table 61: Actemra SWOT Analysis, 2015
Table 62: Product Profile - Otezla
Table 63: Otezla SWOT Analysis, 2015
Table 64: Product Profile - Nucala
Table 65: Completed Trials Demonstrating Nucala as a Potential Treatment for eGPA
Table 66: Nucala SWOT Analysis, 2015
Table 67: Early-Stage Pipeline Products in Vasculitis, November 2015
Table 68: Clinical Benchmark of Key Pipeline Drugs for AAV
Table 69: Clinical Benchmark of Key Pipeline Drugs for LVV, KD, and BD
Table 70: Commercial Benchmark of Key Pipeline Drugs for AAV
Table 71: Commercial Benchmark of Key Pipeline Drugs for LVV, KD, and BD
Table 72: Top-Line Sales Forecasts ($m) for Vasculitis, 2014-2024
Table 73: Key Events Impacting Sales for Vasculitis, 2014-2024
Table 74: Global Vasculitis Disease Market - Drivers and Barriers, 2014-2024
Table 75: Key Launch Dates
Table 76: Key Patent Expiries
Table 77: Average Body Weight and Surface Area Across the 7MM
Table 78: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Classification of Systemic Vasculitides as Defined by CHCC 2012
Figure 2: 7MM, Diagnosed Incident Cases of AAV, Ages =15 Years, Both Sexes, N, 2014-2024
Figure 3: 7MM, Diagnosed Prevalent Cases of AAV, Ages =15 Years, Both Sexes, N, 2014-2024
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of MPA, Ages =15 Years, Both Sexes, N, 2014
Figure 5: 7MM, Age-Standardized Diagnosed Incidence of GPA, Ages =15 Years, Both Sexes, N, 2014
Figure 6: 7MM, Age-Standardized Incidence of eGPA, Ages =15 Years, Both Sexes, N, 2014
Figure 7: 7MM, Diagnosed Incident Cases of LVV, Ages =15 Years, Both Sexes, N, 2014-2024
Figure 8: 7MM, Diagnosed Prevalent Cases of TA, Ages =15 Years, Both Sexes, N, 2014-2024
Figure 9: 7MM, Age-Standardized Diagnosed Incidence of GCA, Ages =15 Years, Both Sexes, N, 2014
Figure 10: 7MM, Age-Standardized Diagnosed Incidence of TA, Ages =15 Years, Both Sexes, N, 2014
Figure 11: 7MM, Diagnosed Incident Cases of BD, Ages =15 Years, Both Sexes, N, 2014-2024
Figure 12: 7MM, Diagnosed Prevalent Cases of BD, Ages =15 Years, Both Sexes, N, 2014-2024
Figure 13: 7MM, Age-Standardized Incidence of BD, Ages =15 Years, Both Sexes, N, 2014
Figure 14: 7MM, Diagnosed Incident Cases of KD, Ages =5 Years, Both Sexes, N, 2014-2024
Figure 15: Competitive Assessment of AAV Pipeline Therapies, 2014-2024
Figure 16: Competitive Assessment of LVV, KD, and BD Pipeline Therapies, 2014-2024
Figure 17: Global Sales for Vasculitis by Region, 2014-2024
Figure 18: Global Sales for Vasculitis by Indication, 2014-2024
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Types of Vasculitis
3.2 Etiology and Pathophysiology
3.2.1 Large Vessel Vasculitis
3.2.2 Kawasaki Disease
3.2.3 ANCA-Associated Small Vessel Vasculitis
3.2.4 Beh?et’s Disease
3.3 Symptoms
3.4 Disease Management
3.4.1 Classification Criteria
3.4.2 Disease Management Guidelines
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Sources Not Used
4.4.3 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for Vasculitis, 2014-2024
4.5.1 Diagnosed Incident Cases of AAV
4.5.2 Diagnosed Prevalent Cases of AAV
4.5.3 Age-Standardized Incidence of AAV
4.5.4 Diagnosed Incident Cases of LVV - TA and GCA
4.5.5 Diagnosed Prevalent Cases of TA
4.5.6 Age-Standardized Incidence of LVV
4.5.7 Diagnosed Incident Cases of BD
4.5.8 Diagnosed Prevalent Cases of BD
4.5.9 Age-Standardized Incidence of BD
4.5.10 Diagnosed Incident Cases of KD
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Current Treatment Options
5.1 Overview
5.2 Product Profiles
5.2.1 Rituxan (Rituximab)
5.2.2 Humira (Adalimumab)
5.2.3 Remicade (Infliximab)
5.2.4 Mycophenolate Mofetil
5.2.5 Cyclophosphamide
5.2.6 Azathioprine
5.2.7 Methotrexate
5.2.8 Glucocorticoids
5.2.9 Intravenous Immunoglobulin
6 Unmet Needs Assessment and Opportunity Analysis
6.1 Overview
6.2 Improved Drug Efficacy and Safety in the Induction Therapy Setting
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Improved Drug Efficacy and Safety in the Maintenance Therapy Setting
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Biomarkers to Predict Responsiveness to Therapy
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Biomarkers to Predict Disease Relapse
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Early and Non-invasive Diagnosis of Vasculitis
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Adjunctive Therapy for the Treatment of KD
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
7 R&D Strategies
7.1 Overview
7.2 Expansion for Key Autoimmune Drugs
7.3 Shift Towards Vasculitis as a Primary Indication
7.4 Clinical Trial Design
7.4.1 Current Clinical Trial Design
7.4.2 Challenges in Vasculitis Clinical Trial Design
8 Pipeline Assessment
8.1 Overview
8.2 Promising Drugs in Clinical Development
8.2.1 Orencia (Abatacept)
8.2.2 Benlysta (Belimumab)
8.2.3 Actemra (Tocilizumab)
8.2.4 Otezla (Apremilast)
8.2.5 Nucala (Mepolizumab)
8.3 Additional Drugs in Development for Vasculitis
9 Pipeline Valuation Analysis
9.1 Clinical Benchmark of Key Pipeline Drugs
9.1.1 AAV
9.1.2 LVV
9.1.3 KD
9.1.4 BD
9.2 Commercial Benchmark of Key Pipeline Drugs
9.2.1 AAV
9.2.2 LVV
9.2.3 KD
9.2.4 BD
9.3 Competitive Assessment
9.3.1 AAV
9.3.2 LVV
9.3.3 KD
9.3.4 BD
9.4 Top Line Ten Year Forecast
9.4.1 US
9.4.2 5EU
9.4.3 Japan
10 Appendix
10.1 Bibliography
10.2 Abbreviations
10.3 Methodology
10.4 Forecasting Methodology
10.4.1 Percent Drug-treated Patients
10.4.2 Drugs Included in Each Therapeutic Class
10.4.3 Launch and Patent Expiry Dates
10.4.4 General Pricing Assumptions
10.4.5 Individual Drug Assumptions
10.4.6 Generic Erosion
10.4.7 Pricing of Pipeline Agents
10.5 Primary Research
10.5.1 Physicians and Specialists Included in this Study
10.5.2 Online Survey of High Prescribing Physicians
10.6 About the Authors
10.6.1 Author
10.6.2 Reviewer
10.6.3 Epidemiologist
10.6.4 Global Director of Therapy Analysis and Epidemiology
10.6.5 Global Head of Healthcare
10.7 About Us
10.8 Disclaimer
1.1 List of Tables
Table 1: Symptoms of Selected Types of Vasculitis
Table 2: Nine Recommendations for the Management of BD
Table 3: Clinical and Laboratory Features of KD
Table 4: Risk Factors and Comorbidities for Vasculitis
Table 5: 2012 Revised CHCC Definitions of Vasculitides
Table 6: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of MPA
Table 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of MPA
Table 8: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of GPA
Table 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of GPA
Table 10: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of eGPA
Table 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of eGPA
Table 12: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of GCA
Table 13: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of TA
Table 14: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of TA
Table 15: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of BD
Table 16: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of BD
Table 17: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of KD
Table 18: 7MM, Sources Not Used in Epidemiological Analysis of AAV, LVV, BD, and KD
Table 19: 7MM, Diagnosed Incident Cases of AAV, Ages =15 Years, Both Sexes, N, 2014-2024
Table 20: 7MM, Diagnosed Prevalent Cases of AAV, Ages =15 Years, Both Sexes, N, 2014-2024
Table 21: 7MM, Diagnosed Incident Cases of LVV, Ages =15 Years, Both Sexes, N, 2014-2024
Table 22: 7MM, Diagnosed Prevalent Cases of TA, Ages =15 Years, Both Sexes, N, 2014-2024
Table 23: 7MM, Diagnosed Incident Cases of BD, Ages =15 Years, Both Sexes, N, 2014-2024
Table 24: 7MM, Diagnosed Prevalent Cases of BD, Ages =15 Years, Both Sexes, N, 2014-2024
Table 25: 7MM, Diagnosed Incident Cases of KD, Ages =5 Years, Both Sexes, N, 2014-2024
Table 26: Leading Treatments for Vasculitis, 2015
Table 27: Current Treatment Options for Vasculitis Across the 7MM, November 2015
Table 28: Product Profile - Rituxan
Table 29: Rituxan SWOT Analysis, 2015
Table 30: Product Profile - Humira
Table 31: Humira SWOT Analysis, 2015
Table 32: Product Profile - Remicade
Table 33: Completed trials demonstrating Remicade as a potential treatment for vasculitis
Table 34: Remicade SWOT Analysis, 2015
Table 35: Product Profile - Mycophenolate Mofetil
Table 36: Evidence for Mycophenolate Mofetil Treatment Therapy in Vasculitis
Table 37: MMF SWOT Analysis, 2015
Table 38: Product Profile - CYC
Table 39: Evidence for cyclophosphamide treatment therapy in vasculitis
Table 40: CYC SWOT Analysis, 2014
Table 41: Product Profile - Azathioprine
Table 42: Evidence for azathioprine treatment therapy in vasculitis
Table 43: Azathioprine SWOT Analysis, 2015
Table 44: Product Profile - Methotrexate
Table 45: Evidence for Methotrexate treatment therapy in vasculitis
Table 46: Methotrexate SWOT Analysis, 2015
Table 47: Product Profile - Glucocorticoids
Table 48: Evidence for Glucocorticoid Treatment Therapy in Vasculitis
Table 49: GC SWOT Analysis, 2015
Table 50: Product Profile - Intravenous Immunoglobulin
Table 51: Evidence for Intravenous Immunoglobulin Therapy in Vasculitis
Table 52: GC SWOT Analysis, 2015
Table 53: Unmet Need and Opportunity in Vasculitis, 2015
Table 54: Vasculitis - Late Stage Pipeline, December 2015
Table 55: Product Profile - Orencia
Table 56: Orencia SWOT Analysis, 2015
Table 57: Product Profile - Benlysta
Table 58: Benlysta SWOT Analysis, 2015
Table 59: Product Profile - Actemra
Table 60: Clinical Trials Demonstrating Actemra as a Potential Treatment for Vasculitis
Table 61: Actemra SWOT Analysis, 2015
Table 62: Product Profile - Otezla
Table 63: Otezla SWOT Analysis, 2015
Table 64: Product Profile - Nucala
Table 65: Completed Trials Demonstrating Nucala as a Potential Treatment for eGPA
Table 66: Nucala SWOT Analysis, 2015
Table 67: Early-Stage Pipeline Products in Vasculitis, November 2015
Table 68: Clinical Benchmark of Key Pipeline Drugs for AAV
Table 69: Clinical Benchmark of Key Pipeline Drugs for LVV, KD, and BD
Table 70: Commercial Benchmark of Key Pipeline Drugs for AAV
Table 71: Commercial Benchmark of Key Pipeline Drugs for LVV, KD, and BD
Table 72: Top-Line Sales Forecasts ($m) for Vasculitis, 2014-2024
Table 73: Key Events Impacting Sales for Vasculitis, 2014-2024
Table 74: Global Vasculitis Disease Market - Drivers and Barriers, 2014-2024
Table 75: Key Launch Dates
Table 76: Key Patent Expiries
Table 77: Average Body Weight and Surface Area Across the 7MM
Table 78: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Classification of Systemic Vasculitides as Defined by CHCC 2012
Figure 2: 7MM, Diagnosed Incident Cases of AAV, Ages =15 Years, Both Sexes, N, 2014-2024
Figure 3: 7MM, Diagnosed Prevalent Cases of AAV, Ages =15 Years, Both Sexes, N, 2014-2024
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of MPA, Ages =15 Years, Both Sexes, N, 2014
Figure 5: 7MM, Age-Standardized Diagnosed Incidence of GPA, Ages =15 Years, Both Sexes, N, 2014
Figure 6: 7MM, Age-Standardized Incidence of eGPA, Ages =15 Years, Both Sexes, N, 2014
Figure 7: 7MM, Diagnosed Incident Cases of LVV, Ages =15 Years, Both Sexes, N, 2014-2024
Figure 8: 7MM, Diagnosed Prevalent Cases of TA, Ages =15 Years, Both Sexes, N, 2014-2024
Figure 9: 7MM, Age-Standardized Diagnosed Incidence of GCA, Ages =15 Years, Both Sexes, N, 2014
Figure 10: 7MM, Age-Standardized Diagnosed Incidence of TA, Ages =15 Years, Both Sexes, N, 2014
Figure 11: 7MM, Diagnosed Incident Cases of BD, Ages =15 Years, Both Sexes, N, 2014-2024
Figure 12: 7MM, Diagnosed Prevalent Cases of BD, Ages =15 Years, Both Sexes, N, 2014-2024
Figure 13: 7MM, Age-Standardized Incidence of BD, Ages =15 Years, Both Sexes, N, 2014
Figure 14: 7MM, Diagnosed Incident Cases of KD, Ages =5 Years, Both Sexes, N, 2014-2024
Figure 15: Competitive Assessment of AAV Pipeline Therapies, 2014-2024
Figure 16: Competitive Assessment of LVV, KD, and BD Pipeline Therapies, 2014-2024
Figure 17: Global Sales for Vasculitis by Region, 2014-2024
Figure 18: Global Sales for Vasculitis by Indication, 2014-2024
AbbVie
J&J
BMS
Roche
Merck
GSK
Biogen
Genentech
Boehringer Ingelheim
Celltrion
Pfizer
Celgene
Sanofi
Eisai
Zydus Cadila
Mitsubishi Tanabe
Alvogen
Hospira
Mundipharma
Novartis
Baxter
UCB
Prometheus
Aspen
Ono
Eli Lilly
Chugaii
AstraZeneca
ChemoCentryx
Delenex
Sobi
Amgen
